5-Methyl-2-furylmethylamine → N-(5-{[(5-methyl-2-furyl)methyl]amino}[1,2,4]triazolo[1,5-a]pyridin-2-yl) nicotinamide
반응식
Br[C:2]1[N:7]2[N:8]=[C:9]([NH:11][C:12](=[O:19])[C:13]3[CH:18]=[CH:17][CH:16]=[N:15][CH:14]=3)[N:10]=[C:6]2[CH:5]=[CH:4][CH:3]=1.[CH3:20][C:21]1[O:27][C:24]([CH2:25][NH2:26])=[CH:23][CH:22]=1>>[CH3:20][C:21]1[O:27][C:24]([CH2:25][NH:26][C:2]2[N:7]3[N:8]=[C:9]([NH:11][C:12](=[O:19])[C:13]4[CH:18]=[CH:17][CH:16]=[N:15][CH:14]=4)[N:10]=[C:6]3[CH:5]=[CH:4][CH:3]=2)=[CH:23][CH:22]=1참가 물질
3
실험 절차
The title compound was prepared following procedure described for example 30 but starting from N-(5-bromo[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide ((B2), 100 mg; 0.31 mmol; 1.0 eq.) and 5-methylfurfurylamine (1.0 mL) as an off-white solid (40 mg, 37%). HPLC, 2.38 min. Rt: (purity 98.6%). LC/MS, M−(ESI): 347.1.
후처리
- customHPLC, 2.38 min